Guess who's the new up-and-comer in pharma? Brazil. Despite a burdensome tax structure, foreign companies are investing heavily in the country, taking advantage of incentives to entry into its generics market. India's Ranbaxy, Germany's Hexal, and Canada's Apotex are among the players in manufacturing. Plus, with almost a quarter of manufacturing capacity unfilled, it's in a perfect position to ramp up for increasing demand. All told, Brazil is among seven "pharmerging" markets expected to grow 12-13 percent next year alone.
- read the story at Outsourcing Pharma